🔗 Share this article

Chancellor Reeves has announced she is planning "specific steps to address household expense pressures" in next month's financial statement.

During an interview with media outlets, she stated that curbing price rises is a shared responsibility of both the administration and the central bank.

The United Kingdom's price growth is projected to be the most elevated among the G7 industrialized countries this calendar year and the following year.

Possible Utility Bill Interventions

Sources suggest the government could intervene to reduce utility costs, for example by slashing the present 5% rate of VAT charged on energy.

A further option is to cut some of the government charges presently included in household expenses.

Fiscal Limitations and Expert Predictions

The administration will receive the latest assessment from the independent fiscal watchdog, the Office for Budget Responsibility, on Monday, which will clarify how much space there is for such measures.

The consensus from the majority of experts is that Reeves will have to introduce higher taxes or budget cuts in order to fulfill her declared fiscal targets.

Earlier on the same day, analysis suggested there was a £22 billion shortfall for the chancellor to fill, which is at the lower end of expectations.

"There's a collective task between the central bank and the administration to continue tackling some of the sources of price increases," the Chancellor told the BBC in the US capital, at the annual meetings of the IMF and global financial institution.

Tax Pledges and International Concerns

While a great deal of the focus has been on expected tax rises, the Treasury chief said the most recent information from the OBR had not changed her commitment to manifesto promises not to raise rates on earnings tax, sales tax or National Insurance.

She blamed an "unpredictable world" with increasing geopolitical and trade issues for the fiscal revenue measures, likely to be directed on those "with the broadest shoulders."

Global Economic Tensions

Commenting on apprehensions about the United Kingdom's commercial links with the Asian nation she said: "The UK's national security invariably take priority."

Recent declaration by Chinese authorities to increase export controls on rare earths and other resources that are essential for advanced tech production led US President Donald Trump to propose an further 100% tariff on imports from China, increasing the prospect of an all-out trade war between the two economic giants.

The US Treasury Secretary called China's move "economic coercion" and "a international production power grab."

Questioned on considering the American proposal to join its dispute with China, the Chancellor said she was "very concerned" by China's measures and called on the Chinese government "to avoid restrictions and restrict access."

She said the action was "harmful for the international commerce and causes further headwinds."

"It is my opinion there are sectors where we need to confront China, but there are also important chances to export to Chinese markets, including banking sector and other sectors of the economic system. We've got to get that equilibrium right."

The Treasury chief also confirmed she was working with international partners "on our own essential resources strategy, so that we are reduced dependence."

Health Service Drug Costs and Funding

Reeves also acknowledged that the cost the National Health Service spends on pharmaceuticals could increase as a result of current discussions with the US government and its pharmaceutical firms, in exchange for lower tariffs and funding.

A number of the biggest global pharmaceutical manufacturers have said lately that they are either pausing or abandoning investments in the United Kingdom, with several blaming the modest returns they are getting.

Recently, the Science Minister said the cost the NHS pays for medicines would need to go up to halt companies and pharmaceutical investment departing from the United Kingdom.

The Chancellor informed media: "It has been observed because of the pricing regime, that clinical trials, new drugs have not been offered in the UK in the extent that they are in other European countries."

"Our aim is to ensure that people receiving treatment from the National Health Service are able to obtain the finest critical medicines in the globe. And so we are looking at this situation, and... aiming to attract more funding into Britain."